Myriad Pharma gets IND approval for new cancer drug

Myriad Pharmaceuticals, Inc. announced that the FDA has approved an Investigational New Drug (IND) application to begin a phase 1 clinical study with its Hsp90 inhibitor, MPC-3100, for the treatment of cancer.

The details can be read here.